Promaxo is innovating the future of cancer care with cutting-edge imaging, AI, and robotic* technologies. Confidently guide MRI-targeted prostate biopsies and treatments in the comfort of your office. The Promaxo MRI System helps identify aggressive prostate cancer earlier¹, providing you with peace of mind that you’re on the right path forward.

Promaxo is a pioneering MedTech company dedicated to enhancing lives through cutting-edge medical imaging, robotics *, and AI. With a focus on patient-centric MRI and minimally invasive robotics, the Company actively sells into the prostate cancer market.

2023年10月12日 · Promaxo MRI 系统是一种开放式 MRI 系统，用于对身体内部结构进行成像。 该系统专为医生办公室设计，无需进行大量设施升级。 由于占地面积和边缘区域有限，该系统可以轻松移动并放置在标准办公室内。

Developer of a portable magnetic resonance imaging (MRI) system designed to diagnose prostate cancer disease.

2023年7月8日 · Promaxo是美国加利福尼亚州奥克兰的医学影像、机器人和人工智能技术公司，所开发的Promaxo MRI于2021年3月获得FDA批准，用于医师在办公室或门诊手术环境对前列腺病变的手术定位。

We are transforming the lives of patients and doctors through our single-sided portable MRI. Fast, safe and convenient. With a compact and adaptable MRI, Promaxo is redefining the standard of...

The Promaxo Robot* leverages real-time imaging and AI to automate and enhance the precision of prostate biopsies and cancer treatments. This advanced technology enables urologists to provide more accurate, personalized care to their patients.

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems, and MRI compatible robotics and machine learning based technologies that enhance patients' lives and redefine the standard of care. Using proprietary technologies protected by 55+ patents, the Company is bringing the first MRI and robotics.

Explore Promaxo's leadership in MRI innovation, enhancing care and quality of life with customer-focused solutions to redefine healthcare standards.

2021年4月2日 · (AV) The Promaxo technology is a confluence of magnetic resonance imaging, robotics, and artificial intelligence. It isn’t just that we made a smaller MRI unit; we are redefining the MRI experience by developing accessible and adaptable technology, protected by 60+ patents, that can be integrated into a standard doctor's office.

2022年7月14日 · Addressing unmet needs—using novel, portable Promaxo MRI technology at the point-of-care (POC) To address the shortcomings of prostate cancer diagnosis and intervention, Oakland, California-based startup, Promaxo, has developed a groundbreaking, next …

2021年3月8日 · OAKLAND, Calif.-- (BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted Promaxo, Inc. (Promaxo) a 510 (k) clearance for its revolutionary office-based MRI system....

This paper describes the workflow of transperineal prostate biopsy (TBx) using the single-sided, low-field Promaxo MRI system (Promaxo Inc., Oakland, California, United States) operating at a field strength ranging between 58 and 74 millitesla (mT).

2021年3月9日 · Promaxo has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its new office-based magnetic resonance imaging (MRI) system. The 510(k) clearance allows practices and hospitals to accurately guide prostate interventions under the Promaxo scanner.

Promaxo, the pioneer in the development of in-office MRI, announced today that it has closed $8M round of financing from a group of super angels and strategic investors. Promaxo will use the funding to accelerate the clinical launch of its award-winning MRI platform in urology practices.

2023年11月9日 · What is the Promaxo MRI system? How the Promaxo MRI system works; Why it made sense for Dr. Pohlman to bring the Promaxo MRI system into an office setting; The flexibility that the Promaxo MRI system provides; How the system required no significant facility upgrades for its installation; Which procedure table is used most commonly for the ...

2021年8月23日 · The Promaxo MRI System is the first single-sided, low-field, and open MRI system developed and cleared by the U.S. FDA for prostate biopsies of target lesions under MRI guidance. The smaller footprint of the system is suitable for office-based procedures and allows board-certified urologists to perform prostate interventions in outpatient settings.

2021年1月28日 · OAKLAND, Calif.-- ( BUSINESS WIRE )-- Promaxo, Inc. (Promaxo), the medical imaging, robotics, and AI technology company, today announced that they have received IRB approval from WCG Clinical...

2023年11月4日 · Stay informed with Promaxo's press releases on the latest advancements in prostate cancer care and how we're transforming patient outcomes.

Oakland, and Cupertino, Calif. — January 13, 2021 – Promaxo, Inc. (Promaxo), the medical imaging, robotics, and AI technology company, and Huami Corp. (NYSE: HMI) today announced closing an investment round of $4.17M led by Huami.